NeoplasmsNCT07339995
Fertility Outcomes of Ovarian Tissue Cryopreservation
An observational study of Neoplasms, run by Chinese University of Hong Kong.
Trial summary
With the advancement of assisted reproductive technology, more young cancer patients can consider having children. Ovaries and testes are important reproductive organs, and drugs, diseases, chemotherapy, and radiotherapy can all damage them. Read more about this study
- Who is it for?
- Ages 0 to 18 years, women only
- Conditions the study is for
- Neoplasms
- What is being tested?
- Ovarian tissue freezing and subsequent auto-transplantation after thawing
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 15 Jan 2026to 14 Jan 2032
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 to 18 years
- Women only
- No healthy volunteers
- Child, Adult
Study population: Patients who have undergone or will undergo ovarian tissue cryopreservation in the Hong Kong Children's Hospital will be invited to join this study.
Who may be able to join
- Patients aged from 0-18 years old and diagnosed with cancer
- Patients who have undergone or will undergo ovarian tissue cryopreservation in Hong Kong Children's Hospital
- For patients under 18 years old, parents/legal guardians will be asked to further sign the consent for them.
Who cannot join
- Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)
- Male patients
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
With the advancement of assisted reproductive technology, more young cancer patients can consider having children. Ovaries and testes are important reproductive organs, and drugs, diseases, chemotherapy, and radiotherapy can all damage them. Reproductive preservation technology aims to protect patients whose reproductive ability has been damaged due to gonadotoxic drug therapy. Women can preserve their reproductive ability by freezing ovarian tissue cryopreservation so that they can have children in the future. Patients who have undergone or will undergo ovarian tissue cryopreservation in Hong Kong Children's Hospital will be invited to participate in the study. Here, we aim to evaluate the outcomes after ovarian tissue cryopreservation.
- Conditions
- Neoplasms
- Being tested
- Ovarian tissue freezing and subsequent auto-transplantation after thawing
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ovarian tissue freezing and subsequent auto-transplantation after thawingOther
Removal of the ovarian tissue will be retrieved via laparoscopic surgery under general anesthesia. The ovarian cortical tissue obtained will be transferred on ice to the laboratory for cryopreservation. After medical treatment, if the patient would like to start a family but has experienced premature ovarian failure, she will have ovarian tissue auto-transplantation after thawing.
What is being measured
The primary outcome is the main question the study is designed to answer.
Surgical complications
Surgical complications after ovarian tissue transplantation
Measured: 15 years
Pregnancy rate
Pregnancy rate after ovarian tissue transplantation
Measured: 15 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jan 2026
- Study start15 Jan 2026 (estimated)
- Primary completion14 Jan 2031 (estimated)
- Study completion14 Jan 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NeoplasmsStudies of the same condition, open and under way.
- More trials run by Chinese University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chinese University of Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Chung Pui Wah Jacqueline, Chinese University of Hong Kong
- Investigators
- Pui Wah Jacqueline Chung, Principal investigator, Chinese University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07339995
- Sponsor's protocol ID
- PAED-2025-067
- Status last verified
- Jan 2026
- First submitted
- 6 Jan 2026
- Last updated
- 14 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 14 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Fertility Outcomes of Ovarian Tissue Cryopreservation
- ClinicalTrials.gov ID
- NCT07339995
- Acronym / sponsor ID
- PAED-2025-067
- Conditions
- Neoplasms
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Chinese University of Hong KongUniversity, hospital or other
- Study start
- 15 Jan 2026 (estimated)
- Primary completion
- 14 Jan 2031 (estimated)
- Study completion
- 14 Jan 2032 (estimated)
- First posted
- 14 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
With the advancement of assisted reproductive technology, more young cancer patients can consider having children. Ovaries and testes are important reproductive organs, and drugs, diseases, chemotherapy, and radiotherapy can all damage them. Reproductive preservation technology aims to protect patients whose reproductive ability has been damaged due to gonadotoxic drug therapy. Women can preserve their reproductive ability by freezing ovarian tissue cryopreservation so that they can have children in the future. Patients who have undergone or will undergo ovarian tissue cryopreservation in Hong Kong Children's Hospital will be invited to participate in the study. Here, we aim to evaluate the outcomes after ovarian tissue cryopreservation.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 0 to 18 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Patients who have undergone or will undergo ovarian tissue cryopreservation in the Hong Kong Children's Hospital will be invited to join this study.
Key inclusion criteria (3 listed)
- Patients aged from 0-18 years old and diagnosed with cancer
- Patients who have undergone or will undergo ovarian tissue cryopreservation in Hong Kong Children's Hospital
- For patients under 18 years old, parents/legal guardians will be asked to further sign the consent for them.
Key exclusion criteria (2 listed)
- Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)
- Male patients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ovarian tissue freezing and subsequent auto-transplantation after thawingRemoval of the ovarian tissue will be retrieved via laparoscopic surgery under general anesthesia. The ovarian cortical tissue obtained will be transferred on ice to the laboratory for cryopreservation. After medical treatment, if the patient would like to start a family but has experienced premature ovarian failure, she will have ovarian tissue auto-transplantation after thawing. | Other | – |
Primary outcome
Surgical complications
Time frame: 15 years
Surgical complications after ovarian tissue transplantation
Pregnancy rate
Time frame: 15 years
Pregnancy rate after ovarian tissue transplantation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Neoplasms
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Pui Wah Jacqueline Chung principal investigator
Chinese University of Hong Kong
Questions about this trial
What is this clinical trial studying?
An observational study of Neoplasms, run by Chinese University of Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Elaine Ng (35052745, elaineng@cuhk.edu.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Surgical complications (time frame: 15 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2026.